source
- Cloudbreak Pharma’s Phase 3 Eye Drop Shows Significant Benefit in Pterygium TrialCloudbreak Pharma reported that its phase 3 trial of CBT-001, a multi‑kinase inhibitor eye drop for pterygium, met both co‑primary endpoints. The study compared two doses of CBT-001 given twice da…
- Experts urge streamlined EU AI framework and higher regulatory literacy for healthcare productsExperts speaking at the RAPS AI in Regulatory Conference in Barcelona called for a more streamlined artificial intelligence framework for healthcare products across Europe. They said the current r…